benefits

Close to the
Ground Truth

Trained with 1M+ cell annotations by 150+ pathologists worldwide, Lunit SCOPE PD-L1 generates analysis results that are close to the ground truth.

Reduced discrepancy

By generating objective results, Lunit SCOPE PD-L1 reduces interpretation discrepancy between pathologists.

Three board-certified pathologists manually evaluated the PD-L1 TPS of 479 NSCLC data, concordantly scoring 81.4% of the cases. Following a revision of these evaluations with Lunit SCOPE PD-L1 assistance, the consensus rate increased to 90.2%. (P < 0.001)

81.4%

W/O AI

90.2%

W/ AI

Sangjoon Choi, et al. (Abstract) Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response, European Journal of Cancer 2022

Patient Enrichment

Based on an accuracy of 96%, Lunit SCOPE PD-L1 finds 50% more patients eligible for immunotherapy compared to human-classified PD-L1(-) patient group.

Lunit SCOPE PD-L1 accurately predicted and rescured ICI responders with TPS < 1% by pathologists.

40

out of 84

40 out of 84 patients (47.6%) annotated control TPS<3% by pathologists were considered as TPS> by AI.

2.7

months

Upon treatment, mPFS of this subgroup was 2.7 months

Sangjoon Choi, et al. (Abstract) Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response, European Journal of Cancer 2022